$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-Q Financial Statement

#000119312513211191 Filed on May 09, 2013

Income Statement

Concept	2013 Q1	2012 Q1
Revenue	$2.750M	$2.750M
YoY Change	0.0%
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$2.357M	$2.357M
YoY Change	0.0%
Gross Profit Margin	85.71%	85.71%
Selling, General & Admin	$1.530M	$1.750M
YoY Change	-12.57%	-43.91%
% of Gross Profit	64.91%	74.25%
Research & Development	$5.081M	$2.664M
YoY Change	90.73%	4340.0%
% of Gross Profit	215.57%	113.03%
Depreciation & Amortization	$2.000K	$42.00K
YoY Change	-95.24%	5.0%
% of Gross Profit	0.08%	1.78%
Operating Expenses	$6.611M	$4.410M
YoY Change	49.91%	38.68%
Operating Profit	-$6.611M	-$2.053M
YoY Change	222.02%
Interest Expense	-$5.000M	-$18.29M
YoY Change	-72.66%	-1370.14%
% of Operating Profit
Other Income/Expense, Net	-$12.06M	-$19.13M
YoY Change	-36.98%
Pretax Income	-$12.06M	-$23.54M
YoY Change	-48.79%	1245.14%
Income Tax	-$2.762M
% Of Pretax Income
Net Earnings	-$16.49M	-$10.54M
YoY Change	56.52%	173.69%
Net Earnings / Revenue	-599.75%	-383.16%
Basic Earnings Per Share	-$1.84	-$1.55
Diluted Earnings Per Share	-$3.359B	-$14.72B
COMMON SHARES
Basic Shares Outstanding	83.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.19M	$8.700M
YoY Change	212.53%	-21.62%
Cash & Equivalents	$17.48M	$8.701M
Short-Term Investments	$9.709M
Other Short-Term Assets	$300.0K	$400.0K
YoY Change	-25.0%	33.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$27.50M	$9.100M
YoY Change	202.22%	-20.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$27.00K	$400.0K
YoY Change	-93.25%	-20.0%
Goodwill	$5.898M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$0.00
YoY Change
Total Long-Term Assets	$33.95M	$19.10M
YoY Change	77.74%	3720.0%
TOTAL ASSETS
Total Short-Term Assets	$27.50M	$9.100M
Total Long-Term Assets	$33.95M	$19.10M
Total Assets	$61.45M	$28.20M
YoY Change	117.91%	136.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.123M	$2.600M
YoY Change	-18.35%	271.43%
Accrued Expenses	$7.478M	$3.500M
YoY Change	113.66%	84.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$26.38M	$27.40M
YoY Change	-3.73%	218.6%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$1.000M
YoY Change	-90.0%
Other Long-Term Liabilities	$6.700M	$5.300M
YoY Change	26.42%
Total Long-Term Liabilities	$6.800M	$6.300M
YoY Change	7.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.38M	$27.40M
Total Long-Term Liabilities	$6.800M	$6.300M
Total Liabilities	$38.14M	$38.80M
YoY Change	-1.7%	351.16%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$132.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.849M
YoY Change
Treasury Stock Shares	675.0K shares
Shareholders Equity	$23.31M	-$10.60M
YoY Change
Total Liabilities & Shareholders Equity	$61.45M	$28.20M
YoY Change	117.91%	136.97%

Cashflow Statement

Concept	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$16.49M	-$10.54M
YoY Change	56.52%	173.69%
Depreciation, Depletion And Amortization	$2.000K	$42.00K
YoY Change	-95.24%	5.0%
Cash From Operating Activities	-$5.331M	-$4.885M
YoY Change	9.13%	61.22%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions	$10.00M
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$10.09M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	-$385.0K
YoY Change	-100.0%	-105.27%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$92.00K	2.153M
YoY Change	-95.73%	-70.47%
NET CHANGE
Cash From Operating Activities	-$5.331M	-4.885M
Cash From Investing Activities	-$10.09M
Cash From Financing Activities	$92.00K	2.153M
Net Change In Cash	-$15.33M	-2.732M
YoY Change	460.98%	-164.74%
FREE CASH FLOW
Cash From Operating Activities	-$5.331M	-$4.885M
Capital Expenditures
Free Cash Flow	-$5.331M	-$4.885M
YoY Change	9.13%	63.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	83463611	shares
CY2011Q3	gale	Cash Contribution In Capital CashContributionInCapital	1500000
CY2012Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13132000	shares
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8701000
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7438137	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5653370
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.79
CY2013Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2013Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13132000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5895000
CY2013Q1	us-gaap	Marketable Securities MarketableSecurities	9709000
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	26379000
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	210000
CY2013Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	16200000
CY2013Q1	us-gaap	Assets Assets	61451000
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17481000
CY2013Q1	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.26
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9350283	shares
CY2013Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	102000
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61451000
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	8000
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83759319	shares
CY2013Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	25285000	shares
CY2013Q1	us-gaap	Goodwill Goodwill	5898000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5571345	shares
CY2013Q1	us-gaap	Business Acquisition Purchase Price Allocation Assets Acquired Liabilities Assumed Net BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet	12827000
CY2013Q1	us-gaap	Liabilities Liabilities	38139000
CY2013Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	74000
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q1	us-gaap	Treasury Stock Value TreasuryStockValue	3849000
CY2013Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	6000
CY2013Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7478000
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27000
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83084319	shares
CY2013Q1	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	7585000
CY2013Q1	us-gaap	Assets Current AssetsCurrent	27502000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	3190725
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	132748000
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	23312000
CY2013Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	51000
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2123000
CY2013Q1	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	111490000
CY2013Q1	gale	Current Contingent Purchase Price Consideration CurrentContingentPurchasePriceConsideration	929000
CY2013Q1	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6656000
CY2013Q1	gale	In Process Research Development InProcessResearchDevelopment	12864000
CY2013Q1	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	15843000
CY2013Q1	gale	Fair Value Of Contingent Purchase Price Consideration FairValueOfContingentPurchasePriceConsideration	6460000
CY2013Q1	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	2024000	shares
CY2013Q1	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	15843000
CY2013Q1	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	779000	shares
CY2013Q1	gale	Sales And Distributions Rights SalesAndDistributionsRights	15086000
CY2002Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11433000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized		shares
CY2012Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13216000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1626000
CY2012Q4	us-gaap	Marketable Securities MarketableSecurities	2678000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15919000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30872000
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	277000
CY2012Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	74000
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3849000
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	6000
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2038000
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	29000
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	535000
CY2012Q4	us-gaap	Assets Assets	54986000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32807000
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.54
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7672384	shares
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	101000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54986000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83595837	shares
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	8000
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2012Q4	us-gaap	Goodwill Goodwill	5898000
CY2012Q4	us-gaap	Liabilities Liabilities	27230000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82920837	shares
CY2012Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	7142000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	36121000
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	132168000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	27756000
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	51000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1976000
CY2012Q4	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	102197000
CY2012Q4	gale	Current Contingent Purchase Price Consideration CurrentContingentPurchasePriceConsideration	935000
CY2012Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6207000
CY2012Q4	gale	In Process Research Development InProcessResearchDevelopment	12864000
CY2012Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	10964000
CY2012Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	10964000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6535000
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	8766000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	715000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	631000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10086000
	us-gaap	Stock Issued1 StockIssued1	978000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10927000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-40712000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-84633000
	us-gaap	Interest Paid InterestPaid	12000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-80819000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	19000
	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	-207000
	us-gaap	Share Based Compensation ShareBasedCompensation	20500000
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	727000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	17481000
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	6367000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-115456000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	37497000
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	220000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	35000
	us-gaap	Net Income Loss NetIncomeLoss	-121351000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5941000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3489000
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	5000000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47820000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	113480000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-320000
	us-gaap	Operating Expenses OperatingExpenses	78692000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3814000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5895000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	102000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	739000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	834000
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-3814000
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	9709000
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	266000
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	37532000
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	50000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3775000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2012000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	101360000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	-1000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	23978000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-85072000
	gale	General And Administrative Expenses GeneralAndAdministrativeExpenses	34044000
	gale	Noncash Rent Expense NoncashRentExpense	29000
	gale	Interest Income InterestIncome	594000
	gale	Research And Development Employee Stock Based Compensation Expense ResearchAndDevelopmentEmployeeStockBasedCompensationExpense	603000
	gale	Research And Development Non Employee Stock Based Compensation Expense ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense	6291000
	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	10967000
	gale	Value Of Restricted Stock Units And Common Stock Issued In Lieu Of Cash Bonuses ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses	634000
	gale	Cash Received In Acquisition CashReceivedInAcquisition	168000
	gale	Cash Refunded Paid For Lease Deposit CashRefundedPaidForLeaseDeposit	-45000
	gale	Cash Transferred With Spin Off Transaction CashTransferredWithSpinOffTransaction	87000
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	4606000
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	2704000
	gale	Common Stock Issued In Connection With Espp CommonStockIssuedInConnectionWithEspp	146000
	gale	General And Administrative Employee Stock Based Compensation GeneralAndAdministrativeEmployeeStockBasedCompensation	10266000
	gale	Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrant FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant	785000
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
	gale	Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants	785000
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	25324000
	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	2402000
	gale	Fair Value Of Common Stock Issued In Exchange For General And Administrative Expenses FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses	3550000
	gale	Fair Value Of Common Stock Issued In Exchange For Licensing Rights FairValueOfCommonStockIssuedInExchangeForLicensingRights	3954000
	gale	Cash Excluding From Net Assets Acquired CashExcludingFromNetAssetsAcquired	168000
	gale	Allocation Of Management Expenses AllocationOfManagementExpenses	551000
	gale	Equipment And Furnishings Exchanged For Common Stock EquipmentAndFurnishingsExchangedForCommonStock	48000
	gale	Net Liabilities Distributed To Common Stock Holders In Rxi Spin Off Net Of Cash Transferred In Spin Off NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOffNetOfCashTransferredInSpinOff	2246000
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	5912000
	gale	Net Proceeds From Issuance Of Convertible Notes Payable NetProceedsFromIssuanceOfConvertibleNotesPayable	1000000
	gale	Issuance Of Common Stock In Exchange Of Outstanding Warrants IssuanceOfCommonStockInExchangeOfOutstandingWarrants	3120000
	gale	Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone	1579000
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	dei	Trading Symbol TradingSymbol	GALE
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	Galena Biopharma, Inc.
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5449000
CY2013Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt
CY2013Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2000
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10087000
CY2013Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><em>Concentrations of Credit Risk</em> — Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of March 31, 2013, the company’s cash equivalents were invested in money market mutual funds. The company’s investment policy does not allow investment in any debt securities rated less than “investment grade” by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. As of March 31, 2013, we had approximately $16,200,000 in interest-bearing accounts above federally insured limits.</font></p> </div>
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised
CY2013Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Reclassifications</i> — Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></p> </div>
CY2013Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10086000
CY2013Q1	us-gaap	Stock Issued1 StockIssued1
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2073000	shares
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5081000
CY2013Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired
CY2013Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-12055000
CY2013Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.11
CY2013Q1	us-gaap	Income Loss From Operations Before Extraordinary Items Per Basic And Diluted Share IncomeLossFromOperationsBeforeExtraordinaryItemsPerBasicAndDilutedShare	-0.11
CY2013Q1	us-gaap	Interest Paid InterestPaid
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	83002323	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
CY2013Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-9293000
CY2013Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets
CY2013Q1	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	248000
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.71
CY2013Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	1000
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-15326000
CY2013Q1	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<div> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i><font style="FONT-FAMILY: Times New Roman" size="2"><i>Derivative Financial Instruments</i> — During the normal course of business, from time to time, the company issues warrants and options to vendors as consideration to perform services. It may also issue warrants as part of a debt or equity financing. The company does not enter into any derivative contracts for speculative purposes.</font></i></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2">The company recognizes all derivatives as assets or liabilities measured at fair value with changes in fair value of derivatives reflected as current period income or loss unless the derivatives qualify for hedge accounting and are accounted for as such. In accordance with FASB ASC Topic 815-40, “ <i>Derivatives and Hedging — Contracts in Entity’s Own Stock,”</i> the value of these warrants is required to be recorded as a liability, as the holders have an option to put the warrants back to the company upon the occurrence of certain events set forth in the warrants.</font></font></p> </div>
CY2013Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.00
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-5024000
CY2013Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations
CY2013Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-9293000
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5444000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0112	pure
CY2013Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock
CY2013Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	5000000
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1530000
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	92000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7749	pure
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-325000
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	6611000
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2762000
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4269000
CY2013Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1000
CY2013Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment
CY2013Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2013Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	116000
CY2013Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2762000
CY2013Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	7031000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	393101	shares
CY2013Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	364000
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22481859	shares
CY2013Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments
CY2013Q1	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><em>Uses of Estimates in Preparation of Financial Statements</em> — The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</font></p> </div>
CY2013Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	440000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.16
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	147000
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2013Q1	gale	Cash Received In Acquisition CashReceivedInAcquisition
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment
CY2013Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4968000
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5331000
CY2013Q1	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P3Y1M21D
CY2013Q1	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	2635674
CY2013Q1	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-5003000
CY2013Q1	gale	General And Administrative Expenses GeneralAndAdministrativeExpenses	1279000
CY2013Q1	gale	Noncash Rent Expense NoncashRentExpense
CY2013Q1	gale	Interest Income InterestIncome	5000
CY2013Q1	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue	808470
CY2013Q1	gale	Proceeds From Technology Revenue ProceedsFromTechnologyRevenue	45000000
CY2013Q1	gale	Proceeds From Technology Revenue Under Condition One ProceedsFromTechnologyRevenueUnderConditionOne	15000000
CY2013Q1	gale	Proceeds From Technology Revenue Under Condition Two ProceedsFromTechnologyRevenueUnderConditionTwo	30000000
CY2013Q1	gale	Research And Development Employee Stock Based Compensation Expense ResearchAndDevelopmentEmployeeStockBasedCompensationExpense	91000
CY2013Q1	gale	Research And Development Non Employee Stock Based Compensation Expense ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense	22000
CY2013Q1	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	124000
CY2013Q1	gale	Value Of Restricted Stock Units And Common Stock Issued In Lieu Of Cash Bonuses ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses
CY2013Q1	gale	Cash Refunded Paid For Lease Deposit CashRefundedPaidForLeaseDeposit
CY2013Q1	gale	Cash Transferred With Spin Off Transaction CashTransferredWithSpinOffTransaction
CY2013Q1	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	5003000
CY2013Q1	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	443000
CY2013Q1	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-443000
CY2013Q1	gale	Common Stock Issued In Connection With Espp CommonStockIssuedInConnectionWithEspp	38000
CY2013Q1	gale	Allocation Of Management Expenses AllocationOfManagementExpenses
CY2013Q1	gale	Equipment And Furnishings Exchanged For Common Stock EquipmentAndFurnishingsExchangedForCommonStock
CY2013Q1	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	-3000
CY2013Q1	gale	Net Liabilities Distributed To Common Stock Holders In Rxi Spin Off Net Of Cash Transferred In Spin Off NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOffNetOfCashTransferredInSpinOff
CY2013Q1	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	54000
CY2013Q1	gale	Net Proceeds From Issuance Of Convertible Notes Payable NetProceedsFromIssuanceOfConvertibleNotesPayable
CY2013Q1	gale	Issuance Of Common Stock In Exchange Of Outstanding Warrants IssuanceOfCommonStockInExchangeOfOutstandingWarrants
CY2013Q1	gale	Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone
CY2013Q1	gale	General And Administrative Employee Stock Based Compensation GeneralAndAdministrativeEmployeeStockBasedCompensation	157000
CY2013Q1	gale	Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrant FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant
CY2013Q1	gale	Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants
CY2013Q1	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity
CY2013Q1	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices
CY2013Q1	gale	Fair Value Of Common Stock Issued In Exchange For General And Administrative Expenses FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses	94000
CY2013Q1	gale	Fair Value Of Common Stock Issued In Exchange For Licensing Rights FairValueOfCommonStockIssuedInExchangeForLicensingRights
CY2013Q1	gale	Minimum Likely Hood For More Likely Than Not Threshold MinimumLikelyHoodForMoreLikelyThanNotThreshold	0.50	pure
CY2013Q1	gale	Estimated Annualized Forfeiture Rate For Options Granted To Employees EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees	0.15	pure
CY2013Q1	gale	Estimated Annualized Forfeiture Rate For Options Granted To Senior Management EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement	0.08	pure
CY2013Q1	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	24600
CY2013Q1	gale	Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents	P90D
CY2013Q1	gale	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	84000	shares
CY2013Q1	gale	Fair Value Of Warrants Exercised FairValueOfWarrantsExercised	124000
CY2013Q1	gale	Amortization Period Of Selling And Distribution Rights AmortizationPeriodOfSellingAndDistributionRights	P10Y
CY2012Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-19114000
CY2012Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt
CY2012Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	42000
CY2012Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised
CY2012Q1	us-gaap	Stock Issued1 StockIssued1
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2664000
CY2012Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired
CY2012Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1221000
CY2012Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-23540000
CY2012Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.49
CY2012Q1	us-gaap	Income Loss From Operations Before Extraordinary Items Per Basic And Diluted Share IncomeLossFromOperationsBeforeExtraordinaryItemsPerBasicAndDilutedShare	-0.52
CY2012Q1	us-gaap	Interest Paid InterestPaid	1000
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47967499	shares
CY2012Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-23540000
CY2012Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets
CY2012Q1	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	427000
CY2012Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits
CY2012Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss
CY2012Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	1000
CY2012Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2732000
CY2012Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions
CY2012Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-24761000
CY2012Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments
CY2012Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	7000
CY2012Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-24761000
CY2012Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19130000
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0106	pure
CY2012Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock
CY2012Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1746000
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2153000
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7569	pure
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-14000
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	4410000
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2012Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
CY2012Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash
CY2012Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.03
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment
CY2012Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	185000
CY2012Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants
CY2012Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	718000
CY2012Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20554835	shares
CY2012Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments
CY2012Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred
CY2012Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-452000
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	426000
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	385000
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2012Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment
CY2012Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2423000
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4885000
CY2012Q1	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-18270000
CY2012Q1	gale	General And Administrative Expenses GeneralAndAdministrativeExpenses	1269000
CY2012Q1	gale	Noncash Rent Expense NoncashRentExpense
CY2012Q1	gale	Interest Income InterestIncome	-16000
CY2012Q1	gale	Research And Development Employee Stock Based Compensation Expense ResearchAndDevelopmentEmployeeStockBasedCompensationExpense	34000
CY2012Q1	gale	Research And Development Non Employee Stock Based Compensation Expense ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense	207000
CY2012Q1	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise
CY2012Q1	gale	Value Of Restricted Stock Units And Common Stock Issued In Lieu Of Cash Bonuses ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses
CY2012Q1	gale	Cash Received In Acquisition CashReceivedInAcquisition
CY2012Q1	gale	Cash Refunded Paid For Lease Deposit CashRefundedPaidForLeaseDeposit
CY2012Q1	gale	Cash Transferred With Spin Off Transaction CashTransferredWithSpinOffTransaction
CY2012Q1	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	18270000
CY2012Q1	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	844000
CY2012Q1	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-844000
CY2012Q1	gale	Common Stock Issued In Connection With Espp CommonStockIssuedInConnectionWithEspp	39000
CY2012Q1	gale	Allocation Of Management Expenses AllocationOfManagementExpenses
CY2012Q1	gale	Equipment And Furnishings Exchanged For Common Stock EquipmentAndFurnishingsExchangedForCommonStock
CY2012Q1	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense
CY2012Q1	gale	Net Liabilities Distributed To Common Stock Holders In Rxi Spin Off Net Of Cash Transferred In Spin Off NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOffNetOfCashTransferredInSpinOff
CY2012Q1	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	1236000
CY2012Q1	gale	Net Proceeds From Issuance Of Convertible Notes Payable NetProceedsFromIssuanceOfConvertibleNotesPayable	500000
CY2012Q1	gale	Issuance Of Common Stock In Exchange Of Outstanding Warrants IssuanceOfCommonStockInExchangeOfOutstandingWarrants
CY2012Q1	gale	Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone
CY2012Q1	gale	General And Administrative Employee Stock Based Compensation GeneralAndAdministrativeEmployeeStockBasedCompensation	194000
CY2012Q1	gale	Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrant FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant
CY2012Q1	gale	Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants
CY2012Q1	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity
CY2012Q1	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	148000
CY2012Q1	gale	Fair Value Of Common Stock Issued In Exchange For General And Administrative Expenses FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses	283000
CY2012Q1	gale	Fair Value Of Common Stock Issued In Exchange For Licensing Rights FairValueOfCommonStockIssuedInExchangeForLicensingRights

Files In Submission

Name	View Source	Status
0001193125-13-211191-index-headers.html	Edgar Link	pending
0001193125-13-211191-index.html	Edgar Link	pending
0001193125-13-211191.txt	Edgar Link	pending
0001193125-13-211191-xbrl.zip	Edgar Link	pending
d515003d10q.htm	Edgar Link	pending
d515003dex103.htm	Edgar Link	pending
d515003dex104.htm	Edgar Link	pending
d515003dex105.htm	Edgar Link	pending
d515003dex106.htm	Edgar Link	pending
d515003dex107.htm	Edgar Link	pending
d515003dex311.htm	Edgar Link	pending
d515003dex312.htm	Edgar Link	pending
d515003dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g515003exa_logo.jpg	Edgar Link	pending
gale-20130331.xml	Edgar Link	completed
gale-20130331.xsd	Edgar Link	pending
gale-20130331_cal.xml	Edgar Link	unprocessable
gale-20130331_def.xml	Edgar Link	unprocessable
gale-20130331_lab.xml	Edgar Link	unprocessable
gale-20130331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2013 Q1 Form 10-Q Financial Statement

#000119312513211191 Filed on May 09, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2013 Q1 Form 10-Q Financial Statement

#000119312513211191 Filed on May 09, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls